Show simple item record

dc.contributor.authorKontsevaya, Irina
dc.contributor.authorLange, Christoph
dc.contributor.authorComella-Del-barrio, Patricia
dc.contributor.authorCoarfa, Cristian
dc.contributor.authorDinardo, Andrew R.
dc.contributor.authorGillespie, Stephen H.
dc.contributor.authorHauptmann, Matthias
dc.contributor.authorLeschczyk, Christoph
dc.contributor.authorMandalakas, Anna M.
dc.contributor.authorMartinecz, Antal
dc.contributor.authorMerker, Matthias
dc.contributor.authorNiemann, Stefan
dc.contributor.authorReimann, Maja
dc.contributor.authorRzhepishevska, Olena
dc.contributor.authorSchaible, Ulrich E.
dc.contributor.authorScheu, Katrin M.
dc.contributor.authorSchurr, Erwin
dc.contributor.authorAbel zur Wiesch, Pia
dc.contributor.authorHeyckendorf, Jan
dc.date.accessioned2022-03-07T12:17:56Z
dc.date.available2022-03-07T12:17:56Z
dc.date.issued2021-05-25
dc.description.abstractStandardised management of tuberculosis may soon be replaced by individualised, precision medicineguided therapies informed with knowledge provided by the field of systems biology. Systems biology is a rapidly expanding field of computational and mathematical analysis and modelling of complex biological systems that can provide insights into mechanisms underlying tuberculosis, identify novel biomarkers, and help to optimise prevention, diagnosis and treatment of disease. These advances are critically important in the context of the evolving epidemic of drug-resistant tuberculosis. Here, we review the available evidence on the role of systems biology approaches – human and mycobacterial genomics and transcriptomics, proteomics, lipidomics/metabolomics, immunophenotyping, systems pharmacology and gut microbiomes – in the management of tuberculosis including prediction of risk for disease progression, severity of mycobacterial virulence and drug resistance, adverse events, comorbidities, response to therapy and treatment outcomes. Application of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach demonstrated that at present most of the studies provide “very low” certainty of evidence for answering clinically relevant questions. Further studies in large prospective cohorts of patients, including randomised clinical trials, are necessary to assess the applicability of the findings in tuberculosis prevention and more efficient clinical management of patients.en_US
dc.identifier.citationKontsevaya, Lange, Comella-Del-barrio, Coarfa, Dinardo, Gillespie, Hauptmann, Leschczyk, Mandalakas, Martinecz, Merker, Niemann, Reimann, Rzhepishevska, Schaible, Scheu, Schurr, Abel zur Wiesch, Heyckendorf. Perspectives for systems biology in the management of tuberculosis. European Respiratory Review. 2021;30(160):1-16en_US
dc.identifier.cristinIDFRIDAID 2003321
dc.identifier.doi10.1183/16000617.0377-2020
dc.identifier.issn0905-9180
dc.identifier.issn1600-0617
dc.identifier.urihttps://hdl.handle.net/10037/24300
dc.language.isoengen_US
dc.publisherEuropean Respiratory Societyen_US
dc.relation.journalEuropean Respiratory Review
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titlePerspectives for systems biology in the management of tuberculosisen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record